Project Grant R01HL183984
- Federal Project Grant Award Summary The University of North Carolina at Chapel Hill received a $773,466 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 3, 2026, with completion targeted for March 31, 2030. This multi-principal investigator research initiative delivers integrated scientific investigation into CXCL5-CXCR2 signaling mechanisms in macrophage cholesterol efflux and...
- Federal Project Grant Award Summary The University of North Carolina at Chapel Hill received a $554,085 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 15, 2026, with completion targeted for March 31, 2030. The research project, titled "Interconnecting Actin Dynamics and Cardiac Metabolic Homeostasis," investigates the mechanisms by which defective mitochondrial clearance (mitophagy)...
- Federal Grant Award Summary The University of North Carolina at Chapel Hill received a $459,838 Project Grant from the National Heart, Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) for the period August 1, 2025 through July 31, 2027. This award supports software development and community engagement activities for the Cardinal open-source software infrastructure, which provides a unified computational platform for simulating all major aspects of...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of North Carolina at Charlotte a $905,820 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) effective September 1, 2025, with completion targeted for July 31, 2027. This award funds development of an innovative automated system for single-cell electrophysiology and contractility measurements in induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). The...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $235,500 Project Grant to the University of California, Irvine on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). This research project, scheduled for completion by March 31, 2028, investigates cardiac complications in female carriers of Duchenne muscular dystrophy (DMD) by examining how dystrophin deficiency affects heart function. The primary deliverable is fundamental...
- Federal Grant Award Summary The University of North Carolina at Chapel Hill received a $171,488 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 30, 2025, with a completion date of August 31, 2026. This grant funds a nationwide examination of access to comprehensive care in sickle cell disease (SCD), a complex inherited blood disorder affecting at least 100,000 Americans and associated...
- Federal Project Grant Award Summary The University of North Carolina at Chapel Hill received a $229,245 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) for the period September 1, 2025 through August 31, 2027. This R03 award supports research to develop improved measurement methods for demographic variables and their associations with cardiovascular health disparities among U.S. adults. The research team...
- Federal Project Grant Award Summary The University of North Carolina at Chapel Hill received a $1,081,420 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded April 1, 2026, with completion by January 31, 2033. The award funds fundamental research investigating cellular signaling pathways that regulate platelet adhesion, activation, and thrombotic responses. The investigator's laboratory will deliver...
- Summary The University of North Carolina at Chapel Hill received a $618,352 Project Grant award dated July 15, 2026, from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct mechanistic research on endothelial dysfunction and cardiovascular disease. The grant funds a four-year research initiative (through March 31, 2031) investigating how mechanical forces—specifically oscillatory shear stress from disturbed blood flow...
- Federal Project Grant Summary Duke University received a $814,943 Project Grant from the National Heart, Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 15, 2026, with completion targeted for March 31, 2030. The award supports the development of non-viral gene therapy systems for cardiac regeneration following myocardial injury. The research deliverables include: (1) development and in vivo testing of cardiac-targeted lipid...
The University of North Carolina at Chapel Hill received a $693,182 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 10, 2026, with completion targeted for March 31, 2030. This award funds research investigating the role of the DDX3X (DEAD-box helicase 3 X-linked) gene in regulating sex-specific differences in cardiac development and congenital heart disease (CHD). The research deliverables include mechanistic studies using conditional genetic models in mice to elucidate how DDX3X regulates sex-dependent cardiac excitation-contraction coupling and the identification of DDX3X target messenger RNAs (mRNAs) critical to female cardiac function, with particular focus on post-transcriptional regulation through mRNA translation. The project addresses a significant scientific gap by examining why certain congenital heart diseases exhibit sex bias, with prior clinical evidence linking DDX3X mutations to CHD in females but not males. The research team will employ molecular and cellular biology techniques to define the cardiac DDX3X protein interactome and characterize its interactions with translation machinery and genes essential to cardiac function. Results from this hypothesis-driven basic research are expected to advance understanding of sex-specific mechanisms in cardiac development and potentially inform therapeutic strategies for preventing or treating sex-differentiated forms of congenital heart disease.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $693.2k | 7/10/26 |